Summary

Although bevacizumab (BEV) has a role in the treatment of colorectal cancer (CRC), it has not been shown to increase the efficacy of doublet chemotherapy in the adjuvant setting. The final results from the Multicentre International Study of Capecitabine±Bevacizumab as Adjuvant Treatment of Colorectal Cancer [QUASAR 2; ISRCTN45133151], a randomized phase 3 trial that tested capecitabine with and without BEV in the adjuvant setting of stage II/III CRC are discussed in this article.